Image
Recommendation
Neoadjuvant chemotherapy – Decision-making
Discuss the benefits and risks of neoadjuvant chemotherapy, including toxicity (with consideration of regulatory status), and effects on breast conservation rate, pathological complete response rate, and survival.
Discuss the benefits and risks of adding a platinum to an anthracycline-containing neoadjuvant chemotherapy regimen. Topics to discuss include those in table 6, and particularly the risk of increased toxicity
Useful Links
How this guidance was developed
This recommendation was adapted from the NICE 2018 guidelines (UK). The source recommendation was based on a systematic review of the evidence conducted up to September 2017 and used wording ('Discuss') indicative of the need for shared decision-making by the source guideline authors. The source recommendation was adapted by making the discussion applicable to all neoadjuvant chemotherapy, not just consideration of a platinum-based agent.
Neoadjuvant chemotherapy – Decision-making
Recommendation
Discuss the benefits and risks of neoadjuvant chemotherapy, including toxicity (with consideration of regulatory status), and effects on breast conservation rate, pathological complete response rate, and survival.
Principles in action
Patient-centred care
Image
Communication
Useful Links
This recommendation was adapted from the NICE 2018 guidelines (UK). The source recommendation was based on a systematic review of the evidence conducted up to September 2017 and used wording ('Discuss') indicative of the need for shared decision-making by the source guideline authors. The source recommendation was adapted by making the discussion applicable to all neoadjuvant chemotherapy, not just consideration of a platinum-based agent.